According to a presentation given yesterday at the ASCO meeting here in Chicago, PET/CT scanning with 68Ga-PSMA-11 is more accurate than 18F-fluciclovine PET/CT at detecting recurrent prostate cancer in men with early biochemical recurrence following radical prostatectomy.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: fluciclovine, fluorine-18, gallium-68, PET, PET/CT, scan | 11 Comments »
A research team at the University of California, Los Angeles (UCLA) is seeking participants for a randomized, Phase III, clinical trial of the utility of 68Ga-PSMA-11 PET/CT molecular imaging for planning of salvage radiotherapy after first-line treatment for localized prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: CT, free, gallium-68, PET, PSMA-11, radiation, salvage, scan, SRT, therapy | 4 Comments »
A new article in the journal Cancer Imaging has provided us with an interesting set of “real world” data on the accuracy of gallium-68 PSMA PET/CT scans in the management of prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: gallium-68, outc omes, PET/CT, PSMA, real world, scan | 14 Comments »
Bayer has announced a new clinical trial of the latest entry in the race for radiopharmaceuticals to treat prostate cancer, joining 177Lu PSMA-617, 225Ac PSMA-617, and 131I MIP-1095. They are trying thorium-227 attached to a PSMA antibody.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: alpha-emitter, radiopharmaceutical, thorium-227, trial | Leave a Comment »
The major, Switzerland-based, global pharmaceutical company Novartis has just agreed to acquire Endocyte — the developer of both Lu-177- PSMA-617 and Ac-225-PSMA-617, which are in clinical trials for the treatment of advanced forms of prostate cancer.
Filed under: Drugs in development | Tagged: Endocyte, Lu-177. Ac-225, Novartis, PSMA, radiopharmaceutical | Leave a Comment »
The “game changer” statement above comes from an independent review of the potential value of gallium-86-labeled prostate-specific molecular antigen (68Ga PSMA) PET scanning in the evaluation of selected men with prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: Diagnosis, gallium-68, PET, prognosis, PSMA, scan, work-up | 4 Comments »
A randomized clinical trial of the 68Ga-PSMA-11 PET indicator for men with a recurrence after radical prostatectomy has just been initiated at the University of California Los Angeles (UCLA).
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: gallium-68, PET, radiation, salvage, scan, trial | 1 Comment »
According to a presentation given last week in San Francisco, lutetium-177 (177Lu) prostate-specific membrane antigen (PSMA) radioligand therapy has significant clinical activity in men with metastatic prostate cancer (as opposed to just in men with very late stages of prostate cancer).
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, lutetium, lutetium-177, outcome, radioligand | 11 Comments »
According to a recent media release, a company called Endocyte has reached agreement with the US Food and Drug Administration about the design of a pivotal Phase III clinical trial that will test the effectiveness and safety of 177Lu-PSMA-617 in men with recurrent, metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: efficacy, lutetium-177, outcome, Phase III, pivotal, PSMA-617, safety, trial | 4 Comments »
The new PSMA-based PET scans provide a way to locate exactly where the cancer has spread to after an unsuccessful prostatectomy.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: change, gallium-68, PET, plan, PSMA, radiation, salvage, scan, Treatment | 6 Comments »
We now have some details from clinical trials of the radiopharmaceutical actinium-225-PSMA-617 (Ac-225-PSMA-617) in very advanced prostate cancer patients.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: actinium-225, mCRPC, PSMA, radiopharmaceutical, trial | 3 Comments »
Because the success or failure of salvage radiation (SRT) hinges upon whether micrometastases are already systemic at the time of treatment, evidence that the cancer is still local improves the odds that SRT will be successful.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: mpMRI, PET/CT, PSMA, radition, salvage, therapy | 1 Comment »
